Epratuzumab for Treating Systemic Lupus Erythematosus
Author Information
Author(s): Dörner Thomas, Kaufmann Joerg, Wegener William A, Teoh Nick, Goldenberg David M, Burmester Gerd R
Primary Institution: Charite Hospital, Berlin, Germany
Hypothesis
The safety and activity of anti-B cell immunotherapy with epratuzumab was evaluated in SLE patients.
Conclusion
Epratuzumab was well tolerated and showed evidence of clinical improvement in patients with systemic lupus erythematosus.
Supporting Evidence
- Total BILAG scores decreased by ≥ 50% in all 14 patients at some point during the study.
- 93% of patients experienced improvements in at least one BILAG B- or C-level disease activity.
- Epratuzumab was well tolerated, with a median infusion time of 32 minutes.
- Drug serum levels were measurable for at least 4 weeks post-treatment.
Takeaway
This study tested a new medicine called epratuzumab to help people with lupus, and it seemed to make them feel better without causing serious side effects.
Methodology
An open-label, single-center study where patients received 360 mg/m2 epratuzumab intravenously every 2 weeks for 4 doses.
Potential Biases
Potential bias due to the open-label design and lack of a control group.
Limitations
The study was small and open-label, which may limit the generalizability of the results.
Participant Demographics
14 Caucasian patients (13 females and 1 male; median age 40 years).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website